AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes
AbbVie is conducting a trial to evaluate the safety and efficacy of ABBV-932 in adults with depressive episodes linked to bipolar I or II disorder.
Therapeutic Area
Therapeutic area intelligence for Bipolar Disorder with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.